Clinical InvestigationAcute Ischemic Heart DiseasePrognostic implications of creatine kinase–MB measurements in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention
Section snippets
Methods
We pooled 2,042 patients with STEMI who were treated with primary PCI within 6 hours of symptom onset and were enrolled in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) (n = 814),8 Direct Inhibition of δ-Protein Kinase C Enzyme to Limit Total Infarct Size in Acute Myocardial Infarction (DELTA MI) (n = 154),9 and Inhibition of δ-Protein Kinase C for Reduction of Infarct Size in Acute Myocardial Infarction (PROTECTION-AMI) (n = 1,074) trials.10 The principal
Baseline demographics and angiographic features
Clinical characteristics and procedural findings of the overall study population stratified by the 3 included trials are shown in Table I. Overall, the median (25th-75th percentiles) age was 60 (52-70) years, and 22.1% patients were female; 12.0% had a prior history of MI. The median total ischemic time was 3.2 (2.4-4.4) hours, 82.3% of patients had an anteriorly located infarction, and 98.3% were Killip class I/II on presentation. At baseline, 69.0% had TIMI flow grade 0/1 in the
Discussion
In this pooled analysis of nearly 1,800 STEMI patients treated with primary PCI with serial core laboratory–determined CK-MB measurements, both peak CK-MB concentration and AUC measurements were independently associated with death or CHF occurring within 90 days and mortality occurring within 6 months. There was no heterogeneity in the magnitude of this prognostic relationship by location of infarction. These findings can be used to guide the application of CK-MB release patterns as efficacy
Conclusions
In STEMI patients treated with primary PCI, both the peak CK-MB concentration and AUC measurement are associated with important 3- to 6-month cardiovascular outcomes independent of other clinical and angiographic characteristics. These findings guide application of CK-MB release patterns after primary PCI as efficacy end points in early-phase clinical trials evaluating new therapies for MI.
Sources of funding
This work was supported by no outside support, but instead was self-funded. The DELTA MI trial was funded by KAI Pharmaceuticals. The PROTECTION-AMI trial was funded by KAI Pharmaceuticals and Bristol-Myers Squibb. The COMMA trial was funded by Procter & Gamble Pharmaceuticals and Alexion Pharmaceuticals Inc.
Conflict of interest disclosures
A. Bagai: Dr Bagai has no relevant disclosures to report.
P.J. Schulte: Dr Schulte has no relevant disclosures to report.
C.B. Granger: Dr Granger received research support from Astellas Pharma US, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic Foundation, Merck & Co, Sanofi-Aventis, and The Medicines Company and consulting for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, Novartis Pharmaceutical Company, Otsuka
Acknowledgements
We thank Peter Hoffmann for his editorial contributions to this manuscript. Mr Hoffmann did not receive compensation for his contributions apart from his employment at the institution where this study was conducted.
References (21)
- et al.
Relation of temporal creatine kinase–MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group
Am J Cardiol
(2000) - et al.
Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction
J Am Coll Cardiol
(2006) - et al.
Prognostic importance of creatine kinase and creatine kinase–MB after primary percutaneous coronary intervention for ST-elevation myocardial infarction
Am Heart J
(2008) - et al.
Comparison of troponin T to creatine kinase and to radionuclide cardiac imaging infarct size in patients with ST-elevation myocardial infarction undergoing primary angioplasty
Am J Cardiol
(2008) - et al.
Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction
JACC Cardiovasc Interv
(2008) - et al.
Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction
Am J Cardiol
(2010) - et al.
Third universal definition of myocardial infarction
Circulation
(2012) - et al.
Clinical measurement of myocardial infarct size. Modification of a method for the estimation of total creatine phosphokinase release after myocardial infarction
Circulation
(1975) - et al.
Creatine kinase–MB assessed in patients with acute myocardial infarction correlates with cardiac magnetic resonance infarct size at 6-month follow up
Hell J Cardiol
(2014) - et al.
Influence of acute myocardial infarct size on acute and one-year mortality
Eur Heart J
(1983)
Cited by (0)
Pamela N. Peterson, MD, MSPH, served as guest editor for this article.